source
- Servier to acquire Edgewise's experimental muscular dystrophy drug in $2.7B dealServier, a French pharmaceutical company, announced it will acquire the muscular dystrophy business of Colorado biotech Edgewise Therapeutics. The deal centers on sevasemten, an experimental oral…
- Medicare launches $50/month coverage for Wegovy and Zepbound but withholds cost to taxpayersMedicare announced a temporary “GLP-1 Bridge” program that will allow adults 65 and older to receive the obesity treatments Wegovy and Zepbound for $50 a month beginning July 1. The program runs t…